Table 1.
Baseline characteristics.
| TCGA-STAD (n = 415) |
ACRG (n = 300) |
TCGA-CRC (n = 380) |
Pembrolizumab-Treated GAC (n = 45) |
|
|---|---|---|---|---|
| Age(year) | 65 (30–90) | 62 (24–86) | 65 (30–90) | 57 (26–78) |
| Gender | ||||
| Male | 268 (64.6%) | 199 (66.3%) | 207 (54.5%) | 32 (71.2%) |
| Female | 147 (35.4%) | 101 (33.7%) | 169 (44.5%) | 13 (28.9%) |
| pStage | ||||
| I | 57 (13.7%) | 30 (10%) | 57 (15%) | 0 (0%) |
| II | 123 (29.6) | 96 (32%) | 118 (31.1) | 0 (0%) |
| III | 171 (41.2%) | 95 (31.7%) | 113 (29.7%) | 0 (0%) |
| IV | 41 (9.9%) | 77 (25.7%) | 52 (13.7%) | 45 (100%) |
| Missing | 23 (5.5%) | 2 (0.6%) | 40 (10.5%) | 0 (0%) |
| Primary tumor site | ||||
| Antrum/Distal | 156 (37.6%) | 155 (51.7%) | NA | NA |
| Cardia/GEJ | 97 (23.4%) | 32 (10.7%) | NA | NA |
| Fundus/Body | 143 (34.5%) | 107 (35.7%) | NA | NA |
| Lauren type | ||||
| Intestinal | 150 (50%) | NA | NA | |
| Diffuse | 142 (47.3%) | NA | NA | |
| OS/PFS (year) | 1.57 (0–10.2) | 4.2 (0.08–8.8) | 2.6 (0–12.3) | 0.5 (0.05–1.4) |
| Pembrolizumab Response |
||||
| CR/PR | NA | NA | NA | 11 (24.4%) |
| SD/PD | NA | NA | NA | 34 (75.6%) |
GEJ: gastroesophageal junction; OS: overall survival; PFS: progression-free survival; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.